SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives $10.50 Consensus PT from Analysts

Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) have earned an average rating of “Moderate Buy” from the eight analysts that are presently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $10.50.

A number of equities research analysts have recently issued reports on the company. Rodman & Renshaw assumed coverage on SAB Biotherapeutics in a research note on Thursday, April 2nd. They set a “buy” rating and a $13.00 price objective on the stock. HC Wainwright dropped their price objective on SAB Biotherapeutics from $9.00 to $7.00 and set a “buy” rating on the stock in a research note on Tuesday, March 10th. Chardan Capital upped their price objective on SAB Biotherapeutics from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Wednesday, March 11th. Zacks Research cut SAB Biotherapeutics from a “hold” rating to a “strong sell” rating in a research note on Thursday, March 12th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of SAB Biotherapeutics in a research note on Friday, April 10th.

Institutional Investors Weigh In On SAB Biotherapeutics

A number of large investors have recently added to or reduced their stakes in SABS. HB Wealth Management LLC bought a new stake in SAB Biotherapeutics in the 3rd quarter valued at $618,000. Dimensional Fund Advisors LP bought a new stake in SAB Biotherapeutics in the 3rd quarter valued at $32,000. ADAR1 Capital Management LLC bought a new stake in SAB Biotherapeutics in the 3rd quarter valued at $30,000. Virtu Financial LLC bought a new stake in SAB Biotherapeutics in the 3rd quarter valued at $40,000. Finally, Commodore Capital LP bought a new stake in SAB Biotherapeutics in the 3rd quarter valued at $8,847,000. Institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Trading Down 0.3%

NASDAQ:SABS opened at $3.68 on Friday. SAB Biotherapeutics has a twelve month low of $1.60 and a twelve month high of $6.60. The company has a quick ratio of 9.46, a current ratio of 9.46 and a debt-to-equity ratio of 0.02. The business has a 50 day moving average price of $3.87 and a two-hundred day moving average price of $3.77. The company has a market cap of $187.50 million, a P/E ratio of -1.59 and a beta of 0.55.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings data on Monday, March 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.30). As a group, analysts expect that SAB Biotherapeutics will post -0.72 EPS for the current fiscal year.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.